Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Cardiovasc. Med.

Sec. Hypertension

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1703770

This article is part of the Research TopicBeyond Childbirth: Cardiovascular Consequences of Hypertensive Disorders in PregnancyView all 4 articles

Vasorin at the Crossroads: Charting New Paths in Preeclampsia Research

Provisionally accepted
Saravanakumar  MurugesanSaravanakumar Murugesan1*Lakshmi  SaravanakumarLakshmi Saravanakumar1Jose-Carlos  Fernandez-Morales,Jose-Carlos Fernandez-Morales,2Tamas  JillingTamas Jilling2Dan  E. BerkowitzDan E. Berkowitz2*
  • 1University of Alabama at Birmingham Epilepsy Center (UABEC), Birmingham, United States
  • 2The University of Alabama at Birmingham, Birmingham, United States

The final, formatted version of the article will be published soon.

Preeclampsia (PE) remains a leading cause of maternal and fetal morbidity and mortality worldwide, yet the precise molecular mechanisms driving its pathology are not fully understood. Recent research has established extracellular vesicles (EVs) as critical mediators in the development of PE-related vascular dysfunction. These nanosized, lipid-bound particles are secreted by cells and serve as a sophisticated system of intercellular communication, carrying functionally active cargo—including proteins, nucleic acids, and lipids—that can modulate physiological and pathological processes via autocrine, paracrine, and endocrine signaling. While the role of EVs-mediated communication in PE has been extensively studied, the specific functions of individual protein components within this cargo remain largely unexplored. Vasorin (VASN), a known regulator of the TGF-β signaling pathway, is a promising candidate for investigation in pregnancy disorder. This review synthesizes existing evidence on VASN's role in PE and discusses its potential contributions to disease pathogenesis. We will highlight the critical need for future research to elucidate VASN's function and evaluate its activity as a promising new therapeutic strategy for a spectrum of pregnancy-related disorders.

Keywords: VASN, Placenta, TGF-β, endothelial dysfunction, Preeclampsia

Received: 11 Sep 2025; Accepted: 17 Oct 2025.

Copyright: © 2025 Murugesan, Saravanakumar, Fernandez-Morales,, Jilling and Berkowitz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Saravanakumar Murugesan, smurugesan@uabmc.edu
Dan E. Berkowitz, dberkowitz@uabmc.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.